Molecule guides
IGF-1 LR3: Escaping the Binding Proteins, and What That Means at the Bench
Two modifications aimed at the binding-protein interface rather than the receptor — why apparent potency rises, how to dissolve a recombinant growth factor, and what its certificate should prove.
With 83 residues, IGF-1 LR3 is a recombinant analogue of human insulin-like growth factor 1 bearing two intentional alterations: arginine replacing glutamate at position 3, and a 13-residue extension on the N-terminus. Each exists for a single purpose — removing the molecule's affinity for the IGF binding proteins that normally hold native IGF-1 captive — while leaving affinity for the IGF-1 receptor largely untouched. What results is a growth factor that stays free both in solution and in serum-containing culture, and that is why it became a routine reagent in cell-culture and receptor-signalling work well before research-chemical catalogues listed it.
We stock IGF-1 LR3 as lyophilized powder in 0.1 mg and 1 mg vials, within the IGF and muscle peptides range.
Defining IGF-1 LR3
Its chemistry is written into the name. "LR3" stands for Long R3 — Long for the extension at the N-terminus, R3 for the arginine at residue 3. IGF-1 itself, the parent, is a single-chain protein of 70 amino acids structurally akin to proinsulin, made predominantly in the liver under growth hormone control, and acting at the IGF-1 receptor, a receptor tyrosine kinase. In circulation, native IGF-1 is almost wholly bound to a family of six IGF binding proteins that govern its availability and cut its unbound half-life to a matter of minutes.
Recombinant expression, not solid-phase synthesis, produces IGF-1 LR3: at 83 residues and 9,117.60 g/mol this is a small protein rather than a peptide that could realistically be built stepwise. Its CAS number is 946870-92-4 and its formula C400H625N111O115S9, and it retains the three disulfide bridges of the native IGF-1 fold.
Origin and structure
Neither modification is aimed at receptor contact; both are aimed at binding-protein contact. Glutamate 3 occupies the N-terminal region of IGF-1 that forms a critical electrostatic contact with the binding proteins, and substituting arginine reverses the local charge — a change reported to cut affinity for the binding proteins by around two orders of magnitude. The 13-residue extension (MFPAMPLSSLFVN) adds further steric obstruction at that same interface while also lifting the isoelectric point of the molecule, which alters how it behaves in solution.
The receptor-binding surface is precisely what the modifications leave alone. Residues contacting IGF-1R lie elsewhere on the fold, so IGF-1 LR3 is still a full agonist at the receptor. Culture systems consistently report a markedly higher apparent potency than native IGF-1 — not from tighter receptor binding, but because so much more of the material is free to bind at all.
The proposed mechanism
The molecule binds the IGF-1 receptor, a disulfide-linked α2β2 tyrosine kinase close kin to the insulin receptor. Binding sets off autophosphorylation within the β-subunit kinase domain and recruitment of insulin receptor substrate proteins, from which two main pathways branch: PI3K/Akt/mTOR, linked in the literature to protein synthesis and survival readouts, and Ras/Raf/MEK/ERK, linked to proliferation readouts. Those are the pathways investigators sample when measuring the response in myoblast systems.
Two mechanistic reservations bear on experimental design. One: IGF-1R and the insulin receptor assemble into hybrid receptors, and IGF-1 analogues keep measurable affinity for isoform A of the insulin receptor, so selectivity here is relative rather than absolute. Two: by escaping binding-protein control, the analogue also deletes a regulatory layer belonging to native IGF-1 biology. Any study using IGF-1 LR3 is intentionally measuring unbuffered receptor activation — valuable for signalling questions, less representative of physiological IGF-1 exposure.
What has been studied
Cell culture and bioprocessing
Its best-established application, and the largest, is as a supplement for serum-free media. Biotechnology literature widely reports the Long R3 form of IGF-1 substituting for insulin in CHO and hybridoma cultures, where resistance to binding proteins that the cells themselves secrete gives it a longer functional life in the medium than native IGF-1 enjoys. This is in-vitro work at industrial scale, with well-characterised outcomes.
Myoblast and skeletal muscle signalling
Studies in C2C12 and primary myoblasts have used the analogue to probe proliferation and differentiation, Akt phosphorylation, and hypertrophic signalling in cultured myotubes. These are cell-level measurements, and the published record does not support extrapolating from them to whole-organism outcomes.
Rodent growth and metabolic models
Most animal work with Long R3 IGF-1 dates from the 1990s, including rat studies reporting stronger growth-promoting effects than an equal number of moles of native IGF-1 — consistent with the binding-protein rationale. Metabolic studies have additionally reported hypoglycaemic responses, which reflect the residual insulin-receptor cross-reactivity noted above.
Comparative analogue work
IGF-1 LR3 is often examined next to IGF-1 DES (1-3), the truncated analogue that tackles the same binding-protein problem by deletion instead of substitution. Where IGFBP proteolysis is active, the two diverge, so selecting between them is a genuine experimental decision rather than a matter of taste — laid out in our IGF-1 LR3 vs IGF-1 DES comparison and in the background piece on why these modifications exist at all.
Presentations available
Single-plate culture work and receptor assays running at nanogram-per-millilitre concentrations suit the 0.1 mg vial, while the 1 mg vial serves extended series that need one lot from start to finish. Sourcing checks are in our IGF-1 LR3 buying guide.
Reconstitution and storage at the bench
Handling a recombinant growth factor differs from handling a short synthetic peptide. Since IGF-1 LR3 dissolves badly at neutral pH, published product literature reconstitutes it in dilute acid — usually 10 mM hydrochloric acid or 0.1% acetic acid — before dilution into buffer or medium. Going straight into a neutral buffer invites incomplete dissolution and aggregation, which surfaces as erratic activity rather than as visible precipitate.
The arithmetic is simple: bringing a 1 mg vial to 1 mL gives 1 mg/mL, that is 1,000 mcg/mL, so 0.1 mL holds 100 mcg. Culture working stocks normally sit several dilutions below that. Because any protein in dilute solution loses material to glass and plastic, adding a carrier protein such as 0.1% bovine serum albumin is standard for working stocks under roughly 10 mcg/mL. The general method is in our reconstitution guide.
Keep lyophilized vials sealed at −20 °C or colder, protected from light and moisture. Aliquot reconstituted material at once and freeze it; for a 9 kDa protein held together by three disulfide bridges, nothing costs more activity than repeated freezing and thawing. Fuller guidance appears in how to store peptides.
Purity, the COA and how to read it
A certificate for a protein made by recombinant expression carries different weight from one for a synthetic peptide. HPLC purity is still the headline, but with an 83-residue product the more telling entries are the mass spectrometry result, which should land on 9,117.60 g/mol and thereby separate the LR3 analogue from native IGF-1 at 7,649 g/mol, and any SDS-PAGE image, which exposes aggregation and truncation products that a reversed-phase trace can conceal. The level of endotoxin matters too for cell-culture use, bacterial expression being the usual source. How these sections relate is covered in our guide to reading a peptide certificate of analysis.
Regulatory position
In the United States, IGF-1 LR3 holds no marketing authorisation as a medicine. Recombinant human IGF-1 (mecasermin), a related but separate molecule, is an approved prescription product for a rare growth disorder; IGF-1 LR3 is not that molecule and cannot substitute for it. Anti-doping rules prohibit IGF-1 and its analogues in sport.
Related molecules and further reading
Its closest neighbours are IGF-1 DES (1-3), the analogue based on truncation, and MGF, the E-domain peptide from the IGF-1 Ec splice variant — which is not a receptor agonist at all and addresses a different question. Wider orientation is in our peptides for muscle growth research overview.
Questions
What does LR3 mean?
It abbreviates Long R3. The "Long" part denotes a 13-residue extension placed on the N-terminus; "R3" denotes the arginine put in place of glutamate at residue 3 of the native sequence. Neither alteration touches the receptor-binding surface — both are aimed at the interface where IGF-1 meets its binding proteins.
Why does it appear more potent than native IGF-1 in culture?
Its receptor affinity is not the reason. Because affinity for the IGF binding proteins is much reduced, a far greater share of what you add remains free in the medium and therefore available to the receptor. Potency differences reported in culture describe availability, not intrinsic binding strength.
How is it reconstituted in the laboratory?
Recombinant IGF-1 analogues go into solution badly at neutral pH, so published product literature reconstitutes them in a dilute acid — 10 mM HCl or 0.1% acetic acid are typical — before dilution into buffer or medium. Adding a carrier protein such as 0.1% BSA to dilute working stocks is standard practice for limiting losses to adsorption.
Which molecular weight belongs on the certificate?
9,117.60 g/mol, with formula C400H625N111O115S9 and CAS 946870-92-4. That value also separates the LR3 analogue from native human IGF-1 at roughly 7,649 g/mol, making it the single most useful identity check on the mass spectrometry trace.
What distinguishes it from IGF-1 DES?
Both lower affinity for the binding proteins, but by opposite routes: LR3 adds an extension and swaps residue 3, whereas DES (1-3) simply removes the first three residues. In tissues where IGFBP proteolysis is active the two behave differently, so choosing between them is a real experimental decision.
Is it the same molecule as prescription mecasermin?
It is not. Mecasermin is recombinant human IGF-1 carrying the native 70-residue sequence, licensed as a prescription medicine for a rare growth disorder. IGF-1 LR3 is an altered 83-residue analogue, and neither substitutes for the other.
Where is it mainly used in research?
In serum-free cell culture and bioprocessing, where it takes the place of insulin in CHO and hybridoma systems; in myoblast signalling studies that sample the Akt and ERK pathways; and in comparative analogue work set against native IGF-1 and IGF-1 DES. The record is in-vitro and preclinical throughout.